Strategic focus Targeting HPV16 driven cancers with a clinically validated Launch-iT platform presents a clear near-term opportunity to partner on immunotherapy programs addressing cervical and head and neck cancers, leveraging their proven antigen-specific T-cell approach.

Platform leverage A scalable, plug-and-play plasmid Launch-iT technology with a tech-transfer ready manufacturing process offers potential for collaboration or licensing to de-risk and accelerate joint development across other persistent viral infections and HPV-driven malignancies.

Clinical momentum Recent leadership hires and board appointment, along with commencement of AVX70371 for chronic hepatitis, signal an active execution plan and growing credibility that can be leveraged to attract co-development agreements and milestone-driven partnerships.

Funding runway With a total funding of around $36M and strategic VLAIO support for hepatitis B programs, there is a window of opportunity to propose co-funding, grant-assisted collaborations, or milestone-based partnerships to de-risk investment.

Therapeutic expansion Beyond oncology, exploration into autoimmune diseases driven by viral infections widens the potential addressable market, suggesting cross-sector opportunities with biotech or large pharma interested in antiviral-immune approaches or preventive frameworks.